Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Income from Continuing Operations for 13 consecutive years, with 108152000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 10.17% year-over-year to 108152000.0, compared with a TTM value of 414670000.0 through Dec 2025, down 162.0%, and an annual FY2025 reading of 412781000.0, down 161.27% over the prior year.
  • Income from Continuing Operations was 108152000.0 for Q4 2025 at Agios Pharmaceuticals, down from 103433000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 947915000.0 in Q3 2024 and bottomed at 112543000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 41775500.0, with a median of 92004000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations surged 1137.97% in 2024, then tumbled 110.91% in 2025.
  • Year by year, Income from Continuing Operations stood at 98584000.0 in 2021, then increased by 5.98% to 92684000.0 in 2022, then dropped by 5.36% to 97653000.0 in 2023, then dropped by 0.53% to 98166000.0 in 2024, then fell by 10.17% to 108152000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for AGIO at 108152000.0 in Q4 2025, 103433000.0 in Q3 2025, and 112543000.0 in Q2 2025.